



Melior Discovery announces the availability of an exclusive model for Alzheimer's Disease (AD)

Murine models of Alzheimer's disease typically rely upon the over-expression of amyloid precursor protein (APP) which is not predictive of the human condition. In contrast, Melior Discovery's proprietary non-transgenic *huA β* mouse model is capable of reliably and predictably assessing plaque deposition relevant to the progression of the human disease. The addition of Melior Discovery's complementary behavioral models provides the capability to effectively evaluate drugs for improvement of cognitive deficits.

huA β Model

Exclusive Melior Model

- Only human A β expressed
- Linear plaque deposition beginning at 6 months
- Cognitive deficits

BENEFITS OF THE *huA β* ALZHEIMER'S DISEASE MODEL FROM MELIOR DISCOVERY:

- » *huA β* is the only model of plaque deposition that expresses normal levels of APP
- » Only model that exclusively expresses human A β – eliminating interference by endogenous murine A β
- » *huA β* model exhibits linear plaque deposition kinetics – comparable to the progression of the human disease
- » Gene-targeted model – Exhibits a very stable phenotype over multiple generations

STANDARD PROTOCOL:

- » Dosing commences at age 8 months and continues for 2 months
- » Novel Object Recognition with age-matched controls
- » Collection of various brain regions, plasma or serum, and cerebral spinal fluid (CSF)
- » Monitor levels of A β 1-42, A β 1-40
- » Histology and plaque load assessment as required
- » Flexibility in study design: Age of animals, N per group, dosing schedule, ELISA's performed

Melior Discovery
860 Springdale Drive
Exton, PA 19341

Phone: (610) 280-0633
Fax: (610) 280-0637
Email: bizdev@meliordiscovery.com
www.meliordiscovery.com